EXACT Sciences Corporation
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $11.79 billion
- Book Value:
- Revenue TTM:
- $2.08 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $1.51 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
EXACT Sciences Corporation had its IPO on 2001-02-01 under the ticker symbol EXAS.
The company operates in the Healthcare sector and Diagnostics & Research industry. EXACT Sciences Corporation has a staff strength of 6,300 employees.
Shares of EXACT Sciences Corporation opened at $65.35 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $63.14 - $65.46, and closed at $63.44.
This is a -4.1% slip from the previous day's closing price.
A total volume of 2,961,300 shares were traded at the close of the day’s session.
In the last one week, shares of EXACT Sciences Corporation have slipped by -1.98%.
EXACT Sciences Corporation's Key Ratios
EXACT Sciences Corporation has a market cap of $11.79 billion, indicating a price to book ratio of 2.603 and a price to sales ratio of 3.9532.
In the last 12-months EXACT Sciences Corporation’s revenue was $2.08 billion with a gross profit of $1.51 billion and an EBITDA of $-423356992. The EBITDA ratio measures EXACT Sciences Corporation's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, EXACT Sciences Corporation’s operating margin was -29.79% while its return on assets stood at -6.01% with a return of equity of -19.39%.
In Q4, EXACT Sciences Corporation’s quarterly earnings growth was a positive 0% while revenue growth was a positive 16.7%.
EXACT Sciences Corporation’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -1.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into EXACT Sciences Corporation’s profitability.
EXACT Sciences Corporation stock is trading at a EV to sales ratio of 4.9219 and a EV to EBITDA ratio of -18.9372. Its price to sales ratio in the trailing 12-months stood at 3.9532.
EXACT Sciences Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.23 billion
- Total Liabilities
- $412.75 million
- Operating Cash Flow
- Capital Expenditure
- $72.88 million
- Dividend Payout Ratio
EXACT Sciences Corporation ended 2023 with $6.23 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.23 billion while shareholder equity stood at $3.04 billion.
EXACT Sciences Corporation ended 2023 with $0 in deferred long-term liabilities, $412.75 million in other current liabilities, 1780000.00 in common stock, $-3265026000.00 in retained earnings and $2.35 billion in goodwill. Its cash balance stood at $242.49 million and cash and short-term investments were $632.06 million. The company’s total short-term debt was $28,366,000 while long-term debt stood at $2.19 billion.
EXACT Sciences Corporation’s total current assets stands at $982.26 million while long-term investments were $0 and short-term investments were $389.56 million. Its net receivables were $158.04 million compared to accounts payable of $74.92 million and inventory worth $118.26 million.
In 2023, EXACT Sciences Corporation's operating cash flow was $-58159000.00 while its capital expenditure stood at $72.88 million.
Comparatively, EXACT Sciences Corporation paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
EXACT Sciences Corporation stock is currently trading at $63.44 per share. It touched a 52-week high of $76.94 and a 52-week low of $76.94. Analysts tracking the stock have a 12-month average target price of $72.06.
Its 50-day moving average was $64.56 and 200-day moving average was $47.16 The short ratio stood at 6.12 indicating a short percent outstanding of 0%.
Around 91.7% of the company’s stock are held by insiders while 9040.8% are held by institutions.
Frequently Asked Questions About EXACT Sciences Corporation
Similar Industry Stocks (Diagnostics & Research)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.